Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health

Cellulite Cream

Obama's Embryonic Stem Cell Proposal Goes 'Only Halfway' To Improving Research, Columnist Says

The Obama administration"s draft guidelines outlining criteria for federal funding of stem cell research "go only halfway toward freeing embryonic stem cell research" because "[s]ome of the most promising investigations will still be denied federal funding," syndicated columnist Froma Harrop writes in a Providence Journal opinion piece. Harrop writes that although "the public supports the research by more than two to one," there is "a vocal minority opposed to this work because it requires the destruction of embryos." According to Harrop, although Obama allowed research on embryos willingly donated by fertility clinic patients and lifted former President George W. Bush"s restrictions limiting federal funding to research on 21 existing stem cell lines, he "wouldn"t budge on the prohibition against funding research that allows for the creation of embryos out of human cells," known as therapeutic cloning. She notes that "therapeutic cloning has little to do with human cloning, which is about making new people and is illegal most everywhere. But say that cloning is being used in research, and many folks think they"re going to have a clone as a neighbor in a few years."Harrop continues, "[B]y allowing the use of embryos from fertility clinics and not those created by researchers, the administration lends credence to the view that embryos are full human beings." However, the "only difference between embryos in fertility clinics and the ones cloned for research is the motive of the people who created them." She concludes, "Obama"s timidity in rewriting the guidelines has slowed down important research and produced more confusion. And for Americans praying for cures from this science, the choice seems rather clear" (Harrop, Providence Journal, 5/28).
generic viagra online

Teva Announces Approval And Launch Of Generic Urso 250(R) And Urso Forte(R)

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted approval for the Company"s Abbreviated New Drug Application (ANDA) for Ursodiol Tablets USP, 250 mg and 500 mg. Teva"s Ursodiol Tablets are the AB-rated generic equivalents of Axcan"s Urso 250® and Urso Forte®, which are indicated for treatment of patients with primary biliary cirrhosis. Shipment of this product has commenced.